Trinity Biotech Slides 4.9% as Over‑Optimistic Valuation and Thin Liquidity Raise Red Flags
Trinity Biotech’s steep 4.88% drop highlights over‑valuation, thin liquidity and a stalled innovation pipeline—investors weigh if the 52‑week high is still justified.
3 minutes to read
